Additional file 4 of Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis

Additional file 4: Table S1. Quality assessment of included studies for quantitative synthesis in the systematic review and meta-analysis. Table S2. Baseline characteristics of included studies for quantitative synthesis in the systematic review and meta-analysis. Table S3. Survival outcomes of included studies for quantitative synthesis in the systematic review and meta-analysis. Majority data is about the HRs (95%CI) of progression-free survival. Table S4. Baseline characteristics of the included individual patient data. Table S5. Baseline characteristics for patients with different baseline ctDNA statuses (+ vs. -) before and after propensity score matching. Table S6. Baseline characteristics for patients with different postoperative ctDNA statuses (+ vs. -) before and after propensity score matching. Table S7. Baseline characteristics for patients with different longitudinal ctDNA statuses (+ vs. -) before and after propensity score matching. Table S8. Survival outcomes by baseline ctDNA status (+ vs. -) based on reconstructed individual patient data. Table S9. Survival outcomes by longitudinal ctDNA status (+ vs. -) based on reconstructed individual patient data. Table S10. Negative and positive predictive values of ctDNA at different timepoints by subgroup analysis. Table S11. Disease-free survival (DFS) analysis by postoperative ctDNA status and whether ACT was conducted or not: Subgroup analyses by pathological stages and types. Table S12. Disease-free survival (DFS) analysis by ctDNA status change from baseline to postoperative timepoints: Subgroup analyses by pathological stages and types.